Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.

Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).

Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.

Awakn Life Sciences announces filing a patent application for the treatment of behavioral addictions with ketamine-assisted psychotherapy.

Pharmather announces a new development agreement with CCBIO to create a proprietary wearable ketamine delivery solution for mental health.

Compass Pathways announces the release of the largest randomized, controlled, double-blind study ever completed on psilocybin-assisted therapy.

MindMed announces the appointment of Schond L. Greenway as its new CFO, bringing a wealth of experience in banking and corporate finance.

The psychedelic drug industry has suddenly attracted the attention of the most influential “power players” on the planet. It’s great news for the industry, but…

Novamind announces the full-scale launch of Frontline KAP, group-based ketamine-assisted therapy for frontline healthcare workers suffering from burnout/stress/trauma, at select clinic locations.